



Original Investigation | Nutrition, Obesity, and Exercise

# Association of Baseline Inflammation With Effectiveness of Nutritional Support Among Patients With Disease-Related Malnutrition

## A Secondary Analysis of a Randomized Clinical Trial

Meret Merker, MD; Martina Felder, BMSc; Louise Gueissaz, BMSc; Rebekka Bolliger, MD; Pascal Tribolet, MSc; Nina Kägi-Braun, MD; Filomena Gomes, PhD; Claus Hoess, MD; Vojtech Pavlicek, MD; Stefan Bilz, MD; Sarah Sigrist, MD; Michael Brändle, MD; Christoph Henzen, MD; Robert Thomann, MD; Jonas Rutishauser, MD; Drahomir Aujesky, MD; Nicolas Rodondi, MD, MAS; Jaques Donzé, MSc; Zeno Stanga, MD; Beat Mueller, MD; Philipp Schuetz, MD, MPH

### Abstract

**IMPORTANCE** Inflammation is a key driver of malnutrition during illness and is often accompanied by metabolic effects, including insulin resistance and reduction of appetite. However, it still remains unclear if inflammation influences the response to nutritional support among patients with disease-related malnutrition.

**OBJECTIVE** To examine whether patients' baseline inflammatory status is associated with the effect of nutritional support on 30-day mortality.

**DESIGN, SETTING, AND PARTICIPANTS** This is a secondary analysis of the Effect of Early Nutritional Support on Frailty, Functional Outcomes, and Recovery of Malnourished Medical Inpatients Trial (EFFORT), a randomized clinical trial conducted in 8 Swiss hospitals from April 2014 to February 2018. A total of 1950 participants who had C-reactive protein measurements at the time of admission were included in this secondary analysis. Data analysis was conducted between June and July 2019.

**INTERVENTIONS** Hospitalized patients at risk for malnutrition were randomly assigned to receive protocol-guided individualized nutritional support to reach protein and energy goals (intervention group) or standard hospital food (control group).

**MAIN OUTCOMES AND MEASURES** The primary end point was 30-day mortality. Based on C-reactive protein levels at admission, patients were stratified into groups with low, moderate, or high inflammation (<10 mg/L, 10-100 mg/L, and >100 mg/L, respectively).

**RESULTS** A total of 1950 patients (median [interquartile range] age, 75 [65-83] years; 1025 [52.6%] men) were included; 533 (27.3%) had low levels of inflammation, 894 (45.9%) had moderate levels of inflammation, and 523 (26.8%) had high levels of inflammation. Compared with the control group, patients receiving nutritional support showed a significant reduction in 30-day mortality, regardless of C-reactive protein level (adjusted odds ratio, 0.61; 95% CI, 0.43-0.86;  $P = .005$ ). In the subgroup of patients with high inflammation, there was no beneficial effect of nutritional support (adjusted odds ratio, 1.32; 95% CI, 0.70-2.50;  $P = .39$ ), providing evidence that inflammation has a significant modifying association ( $P$  for interaction = .005).

**CONCLUSIONS AND RELEVANCE** Based on this secondary analysis of a multicenter randomized trial, a patient's admission inflammatory status was associated with their response to nutritional support. If validated in future clinical trials, nutritional support may need to be individualized based

(continued)

### Key Points

**Question** Does nutritional support have a similar effect on 30-day mortality among patients with high inflammation compared with patients with low or moderate inflammation?

**Findings** In this secondary analysis of a Swiss multicenter trial, including 1950 patients at risk of malnutrition, patients with high levels of inflammation based on their levels of C-reactive protein at admission were not associated with a beneficial effect of nutritional support on 30-day mortality compared with the overall population, suggesting that inflammation has a significant modifying association.

**Meaning** Based on this secondary analysis of a multicenter randomized trial, patients' inflammatory status at admission was associated with their response to nutritional support and may be considered when individualizing the nutritional management of medical inpatients.

+ Visual Abstract

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

**Open Access.** This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

on a patient's initial presentation and markers of inflammation. These results may also help to explain some of the heterogeneity in treatment effects of nutrition seen in previous critical care trials.

**TRIAL REGISTRATION** ClinicalTrials.gov Identifier: [NCT02517476](https://clinicaltrials.gov/ct2/show/study/NCT02517476)

*JAMA Network Open.* 2020;3(3):e200663. doi:10.1001/jamanetworkopen.2020.0663

## Introduction

Disease-related malnutrition is a frequent condition among hospitalized medical inpatients, with a prevalence of 20% to 50%.<sup>1-3</sup> The 2019 Effect of Early Nutritional Support on Frailty, Functional Outcomes, and Recovery of Malnourished Medical Inpatients Trial (EFFORT)<sup>4</sup> demonstrated that starting individualized nutritional support early reduces complications and mortality among medical inpatients at risk for malnutrition. Interestingly, there was little evidence in this trial for subgroup effects regarding nutritional status and type of medical disease. Nevertheless, independent of medical disease, patients' inflammatory status could influence their response to nutritional support for several reasons.

Inflammation has several metabolic effects, including an increase in insulin resistance and reduction of appetite, leading to an inhibition of nutrition entering cells.<sup>5,6</sup> In fact, independent of underlying disease, inflammation is thought to be a key driver for disease-related anorexia, reduced food intake, and muscle catabolism. This may also partly explain the inferior patient outcomes associated with inflammation, which include longer hospital stays and increased mortality.<sup>7,8</sup> The relevance of inflammation in the pathogenesis of malnutrition is also reflected in its classification by the European Society of Clinical Nutrition and Metabolism (ESPEN). They recommend dividing malnutrition into disease-related malnutrition with and without inflammation.<sup>9</sup> *Disease-related malnutrition with inflammation* is defined as underlying diseases causing inflammation with a consecutive lack of food intake or as uptake with a negative nutrient balance.<sup>10</sup> Although several mainly preclinical studies have evaluated the relevance of inflammation on malnutrition, there is a lack of clinical data investigating whether the inflammatory status of a patient influences treatment response to nutritional support.

To close this gap, we conducted a secondary analysis of a prospective randomized clinical trial that included consecutive patients with malnutrition at the time of hospital admission. We investigated whether the inflammatory status of patients, as mirrored by their levels of C-reactive protein (CRP) at admission, was associated with treatment response within the trial and whether nutritional support was associated with CRP kinetics over time. Knowledge of such factors could improve our physiopathological understanding of the role nutrition plays during acute illness and may enable a more individualized nutritional approach to patients.

## Methods

### Study Design and Setting

This is a secondary analysis of EFFORT, a pragmatic, investigator-initiated, open-label, multicenter trial that was undertaken in 8 Swiss hospitals from April 2014 to February 2018. Between June and July 2019, we performed this secondary analysis. Reporting of the results follows the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline for randomized clinical trials.<sup>11</sup> The Ethics Committee of Northwestern Switzerland approved the study protocol, and all patients or their authorized representatives provided written informed consent. The main aim was to assess the effects of early nutritional support on patient outcomes in the medical inpatient setting. Rationale for the trial,

design details, and eligibility features<sup>12</sup> as well as the main results<sup>4</sup> have been published previously. The trial protocol is available in [Supplement 1](#).

### Patient Population and Management

In EFFORT, consecutive patients at nutritional risk (ie, Nutritional Risk Screening [NRS] 2002 total score  $\geq 3$  points<sup>13</sup>) with an expected hospital stay of at least 5 days were enrolled if they were willing to provide informed consent. Patients were excluded if they were initially admitted to intensive care units or surgical units; were unable to ingest oral nutrition; were already receiving nutritional support before admission; had a terminal condition (ie, end-of-life situation); were hospitalized because of anorexia nervosa, acute pancreatitis, acute liver failure, cystic fibrosis, or stem cell transplantation; had undergone gastric bypass surgery; had contraindications for nutritional support; or were previously included in the trial. While EFFORT included a total of 2028 patients, this secondary analysis included 1950 patients (96.2%) whose CRP levels were measured at time of admission as part of the clinical routine.

Upon admission, medical diagnosis according to *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)* codes, sociodemographic and anthropometric data, baseline muscle strength, and functional status (using the Barthel scale) were assessed in all patients based on the trial protocol. Following discharge, masked study nurses contacted patients after 30 and 180 days for a structured telephone interview. Prespecified health-related outcomes were systematically assessed at these points.

### Patient Groups and End Points

We allocated patients to 3 groups according to their inflammatory status at time of admission. Low inflammation was defined as CRP levels less than 10 mg/L, moderate as 10 mg/L to 100 mg/L, and high as greater than 100 mg/L (to convert CRP to nanomoles per liter, multiply by 9.524). These cutoffs were predefined based on a clinical rationale and prior experience with CRP levels among patients with various degrees of inflammation.<sup>14</sup>

Our main aim was to investigate whether a patient's inflammatory status was associated with the effect of nutritional support on important outcomes. We compared different end points among patients receiving protocol-guided personalized nutritional support (ie, the intervention group) with those receiving standard hospital food (ie, the control group) within the predefined subgroups.

The primary end point was all-cause mortality after 30 days. Secondary end points were 180-day mortality, major complications, decline in functional status according to the Barthel scale at 30 and 180 days, and length of hospital stay. Adverse outcomes were defined as all-cause mortality, admission to intensive care units, and nonelective hospital readmission. The Barthel scale measures performance in activities of daily living and comprises 2 groups of items, 1 related to self-care (ie, feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and the other to mobility (ie, ambulation, transfers, and stair climbing). We used the German version, which has scores ranging from 100 to 0, with lower scores indicating more severe disability. We defined decline as a reduction of 10% or more on the Barthel scale from time of admission.

### Statistical Analysis

Continuous variables were expressed as medians and interquartile ranges (IQRs), and frequencies were expressed as percentages and counts. We calculated logistic regression analysis and report odds ratios (ORs) and 95% CIs. We adjusted all analyses for predefined factors, including sex, age, baseline nutritional risk (ie, NRS 2002 score), study center, Barthel scale at baseline, main diagnosis, cardiovascular disease, renal disease, and cancer. We studied the effect of nutritional support overall and in subgroups by comparing outcomes among patients receiving nutritional support with control patients not receiving support. We included interaction terms in the statistical models to investigate whether there was evidence for effect modification due to baseline inflammatory status of patients (ie, low, moderate, or high inflammation). As a sensitivity analysis, we also included CRP as a

continuous marker in the model. Finally, we performed a subgroup analysis limiting data to patients with a main diagnosis of infection to understand whether inflammation or infection was the main driver of results.


All statistical analyses were performed using Stata version 15.1 (StataCorp).  $P < .05$  was considered statistically significant, and all tests were 2-tailed.

## Results

### Patient Population

From an initial population of 2028 EFFORT trial patients (Figure 1), we had available CRP levels for 1950 patients (96.2%), of whom 533 (27.3%) had low levels of inflammation (CRP levels <10 mg/L), 894 (45.9%) had moderate levels of inflammation (CRP levels 10-100 mg/L), and 523 (26.8%) had high levels of inflammation (CRP levels >100 mg/L). Baseline characteristics for the overall population and those stratified according to inflammation status are shown in Table 1. The median (IQR) age of the population was 75 (65-83) years, and 1025 (52.6%) were men. All patients were at nutritional risk, with 598 (30.7%), 751 (38.5%), 499 (25.6%), and 102 (5.2%) having NRS 2002 scores of 3, 4, 5 and at least 6 points, respectively. The most common main diagnoses were infectious disease (592 [30.4%]), cancer (360 [18.5%]), and cardiovascular disease (197 [10.1%]), with significant differences among inflammation groups. For example, more patients with infectious diseases were in the high inflammation group than in the moderate or low inflammation groups (314 [60.0%] vs 235 [26.3%] vs 43 [8.1%];  $P < .001$ ), and more patients with cardiovascular disease were in the low inflammation group than in the moderate or high inflammation groups (72 [13.5%] vs 114 [12.8%] vs 11 [2.1%];  $P < .001$ ). The eTable in Supplement 2 also shows patient baseline and mean

Figure 1. Flow of Patients Through the Trial



CRP indicates C-reactive protein.

nutritional intake data during the hospital stay according to randomization group and stratified according to CRP group. Overall, baseline data were well balanced according to randomization groups within CRP groups. There were significantly higher mean calorie and protein intakes among patients in the intervention group compared with patients in the control group, regardless of CRP level (eg, high inflammation group: mean [SD] protein intake, 54.6 [23.5] g/d vs 44.7 [19.5] g/d;  $P < .001$ ; mean [SD] calorie intake, 1432 [606] kcal/d vs 1138 [449] kcal/d;  $P < .001$ ).

Table 1. Baseline Characteristics Overall and Stratified by Inflammation Level

| Characteristic              | No. (%)            |                               |                                  |                                | P Value |
|-----------------------------|--------------------|-------------------------------|----------------------------------|--------------------------------|---------|
|                             | Overall (N = 1950) | CRP Levels <10 mg/L (n = 533) | CRP Levels 10-100 mg/L (n = 894) | CRP Levels >100 mg/L (n = 523) |         |
| Age, median (IQR), y        | 75 (65-83)         | 74 (62-83)                    | 76 (67-83)                       | 74 (66-81)                     | .03     |
| Men                         | 1025 (52.6)        | 250 (46.9)                    | 490 (54.8)                       | 285 (54.5)                     | .009    |
| <b>BMI</b>                  |                    |                               |                                  |                                |         |
| Median (IQR)                | 24.0 (21.0-28.0)   | 23.0 (20.0-27.0)              | 24.0 (21.0-28.0)                 | 25.0 (21.5-28.0)               | <.001   |
| <18.5                       | 173 (8.9)          | 72 (13.5)                     | 67 (7.5)                         | 34 (6.5)                       | <.001   |
| 18.5-25                     | 1017 (52.3)        | 288 (54.0)                    | 473 (53.1)                       | 256 (49.2)                     |         |
| >25                         | 754 (38.8)         | 173 (32.5)                    | 351 (39.4)                       | 230 (44.2)                     |         |
| <b>NRS 2002 score</b>       |                    |                               |                                  |                                |         |
| 3                           | 598 (30.7)         | 198 (37.1)                    | 294 (32.9)                       | 106 (20.3)                     | <.001   |
| 4                           | 751 (38.5)         | 211 (39.6)                    | 328 (36.7)                       | 212 (40.5)                     |         |
| 5                           | 499 (25.6)         | 112 (21.0)                    | 232 (26.0)                       | 155 (29.6)                     |         |
| ≥6                          | 102 (5.2)          | 12 (2.3)                      | 40 (4.5)                         | 50 (9.6)                       |         |
| <b>Main diagnosis</b>       |                    |                               |                                  |                                |         |
| Cardiovascular disease      | 197 (10.1)         | 72 (13.5)                     | 114 (12.8)                       | 11 (2.1)                       | <.001   |
| Infectious disease          | 592 (30.4)         | 43 (8.1)                      | 235 (26.3)                       | 314 (60.0)                     |         |
| Metabolic disorder          | 60 (3.1)           | 35 (6.6)                      | 24 (2.7)                         | 1 (0.2)                        |         |
| Gastrointestinal disease    | 156 (8.0)          | 52 (9.8)                      | 86 (9.6)                         | 18 (3.4)                       |         |
| Renal disease               | 66 (3.4)           | 18 (3.4)                      | 38 (4.3)                         | 10 (1.9)                       |         |
| Cancer                      | 360 (18.5)         | 89 (16.7)                     | 174 (19.5)                       | 97 (18.5)                      |         |
| Pulmonary disease           | 117 (6.0)          | 31 (5.8)                      | 62 (6.9)                         | 24 (4.6)                       |         |
| Neurological disorder       | 91 (4.7)           | 64 (12.0)                     | 22 (2.5)                         | 5 (1.0)                        |         |
| Frailty                     | 188 (9.6)          | 84 (15.8)                     | 80 (8.9)                         | 24 (4.6)                       |         |
| Other                       | 123 (6.3)          | 45 (8.4)                      | 59 (6.6)                         | 19 (3.6)                       |         |
| <b>Comorbidities</b>        |                    |                               |                                  |                                |         |
| Coronary heart disease      | 539 (27.6)         | 157 (29.5)                    | 254 (28.4)                       | 128 (24.5)                     | .15     |
| Congestive heart failure    | 341 (17.5)         | 86 (16.1)                     | 180 (20.1)                       | 75 (14.3)                      | .01     |
| Hypertension                | 1062 (54.5)        | 287 (53.8)                    | 488 (54.6)                       | 287 (54.9)                     | .94     |
| Cerebrovascular disease     | 158 (8.1)          | 49 (9.2)                      | 69 (7.7)                         | 40 (7.6)                       | .56     |
| Peripheral arterial disease | 175 (9.0)          | 50 (9.4)                      | 87 (9.7)                         | 38 (7.3)                       | .27     |
| Chronic kidney disease      | 618 (31.7)         | 147 (27.6)                    | 308 (34.5)                       | 163 (31.2)                     | .03     |
| Diabetes                    | 407 (20.9)         | 106 (19.9)                    | 194 (21.7)                       | 107 (20.5)                     | .69     |
| COPD                        | 291 (14.9)         | 75 (14.1)                     | 143 (16.0)                       | 73 (14.0)                      | .47     |
| Dementia                    | 72 (3.7)           | 24 (4.5)                      | 31 (3.5)                         | 17 (3.3)                       | .50     |
| Malignant disease           | 647 (33.2)         | 143 (26.8)                    | 309 (34.6)                       | 195 (37.3)                     | <.001   |
| <b>Clinical findings</b>    |                    |                               |                                  |                                |         |
| <b>Barthel scale</b>        |                    |                               |                                  |                                |         |
| Median (IQR)                | 90 (70-100)        | 90 (75-100)                   | 90 (70-100)                      | 85 (70-95)                     | <.001   |
| <90 Points                  | 1143 (58.6)        | 268 (50.3)                    | 542 (60.6)                       | 333 (63.7)                     | <.001   |
| <b>Admission CRP level</b>  |                    |                               |                                  |                                |         |
| Median (IQR)                | 34.0 (8.0-110.0)   | 4.0 (3.0-5.3)                 | 35.0 (18.8-62.6)                 | 172.0 (133.0-230.0)            | <.001   |
| Mean (SD)                   | 71.8 (85.6)        | 4.3 (2.3)                     | 41.9 (26.6)                      | 191.5 (75.0)                   | <.001   |

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; IQR, interquartile range; NRS, Nutritional Risk Screening.

SI conversion factor: To convert CRP to nanomoles per liter, multiply by 9.524.

### Effect of Nutritional Support on 30-Day Mortality According to Inflammation Groups

Overall, there was a significant risk reduction for 30-day mortality among patients receiving nutritional support, with 7.0% (67 of 978) fulfilling the primary end point in the intervention group compared with 9.7% (94 of 972) in the control group (Figure 2). This effect was also confirmed by logistic regression analysis adjusted for sex, age, baseline nutritional risk (ie, NRS 2002 score), study center, Barthel scale at baseline, main diagnosis, cardiovascular disease, renal disease and cancer, with an adjusted OR of 0.61 (95% CI, 0.43-0.86;  $P = .005$ ) (Table 2). To further understand whether baseline inflammation influenced the effect of nutritional support, we investigated mortality effects within subgroups based on inflammation and calculated interaction statistics. The effects of nutritional support remained robust among patients with low inflammation (adjusted OR, 0.34; 95% CI, 0.10-1.09;  $P = .02$ ) and moderate inflammation (adjusted OR, 0.41; 95% CI, 0.24-0.68;  $P = .001$ ) (Table 2). However, among patients with high inflammatory status, there was no significant benefit of nutritional support (adjusted OR, 1.32; 95% CI, 0.70-2.50;  $P = .39$ ), with evidence for interaction ( $P$  for interaction = .005). Figure 2 shows a time-to-event analysis regarding the primary end point overall and stratified according to inflammation groups.

In a sensitivity analysis, we also found that when CRP was included in the model as a continuous variable, there was evidence for effect modification for CRP on the association of nutritional support and mortality ( $P$  for interaction = .005). We also performed a subgroup analysis limited to 592 patients (30.4%) with a systemic infection as their main admission diagnosis. Within this subgroup, the strength of the association of nutritional support with 30-day mortality again differed among CRP groups with adjusted ORs of 0.78 (95% CI, 0.05-13.40;  $P = .88$ ) and 0.51 (95% CI, 0.17-1.53;

Figure 2. Kaplan-Meier Estimate for Time to Death Within 30 Days According to Inflammatory Status




Table 2. Primary and Secondary Outcomes

| End Point                      | Overall                  |         |                         | CRP Level <10 mg/L       |         |                         | CRP Level 10-100 mg/L    |         |                         | CRP Level >100 mg/L      |         |                         |
|--------------------------------|--------------------------|---------|-------------------------|--------------------------|---------|-------------------------|--------------------------|---------|-------------------------|--------------------------|---------|-------------------------|
|                                | OR (95% CI) <sup>a</sup> | P Value | P Value for Interaction | OR (95% CI) <sup>a</sup> | P Value | P Value for Interaction | OR (95% CI) <sup>a</sup> | P Value | P Value for Interaction | OR (95% CI) <sup>a</sup> | P Value | P Value for Interaction |
| 30-d Mortality                 | 0.61 (0.43 to 0.86)      | .005    | .02                     | 0.34 (0.10 to 1.09)      | .02     | .28                     | 0.41 (0.24 to 0.66)      | .001    | .046                    | 1.32 (0.70 to 2.50)      | .39     | .005                    |
| 180-d Mortality                | 0.79 (0.63 to 1.01)      | .06     | .28                     | 0.72 (0.40 to 1.31)      | .28     | .29                     | 0.78 (0.55 to 1.07)      | .12     | .86                     | 0.95 (0.58 to 1.55)      | .82     | .57                     |
| Adverse outcome within 30 d    | 0.74 (0.59 to 0.91)      | .006    | .61                     | 0.79 (0.32 to 1.95)      | .61     | .76                     | 0.66 (0.48 to 0.89)      | .008    | .52                     | 0.82 (0.54 to 1.26)      | .38     | .93                     |
| ICU admission within 30 d      | 0.86 (0.47 to 1.58)      | .63     | .56                     | 0.67 (0.18 to 2.54)      | .56     | .56                     | 1.09 (0.44 to 2.70)      | .84     | .28                     | 0.68 (0.16 to 2.88)      | .60     | .51                     |
| Rehospitalization within 30 d  | 0.93 (0.68 to 1.29)      | .67     | .68                     | 1.16 (0.58 to 2.32)      | .68     | .34                     | 0.80 (0.51 to 1.26)      | .35     | .55                     | 0.90 (0.46 to 1.80)      | .77     | .74                     |
| Major complication within 30 d | 0.92 (0.65 to 1.31)      | .63     | .46                     | 0.72 (0.29 to 1.78)      | .46     | .46                     | 0.85 (0.53 to 1.36)      | .50     | .87                     | 1.19 (0.59 to 2.38)      | .63     | .43                     |
| Barthel Scale decline, 30 d    | 0.65 (0.49 to 0.87)      | .004    | .48                     | 0.76 (0.36 to 1.61)      | .48     | .69                     | 0.52 (0.35 to 0.78)      | .002    | .41                     | 0.89 (0.50 to 1.56)      | .67     | .22                     |
| Barthel Scale decline, 180 d   | 1.00 (0.81 to 1.24)      | .98     | .05                     | 1.55 (0.99 to 2.41)      | .05     | .21                     | 0.91 (0.67 to 1.24)      | .56     | .51                     | 0.83 (0.52 to 1.32)      | .44     | .49                     |
| Length of hospital stay, d     | -0.33 (-0.89 to 0.23)    | .25     | .42                     | -0.40 (-1.37 to 0.57)    | .42     | .56                     | -0.25 (-1.09 to 0.59)    | .55     | .55                     | -0.46 (-1.71 to 0.79)    | .47     | .85                     |

Abbreviations: CRP, C-reactive protein; ICU, intensive care unit; OR, odds ratio. SI conversion factor: To convert CRP to nanomoles per liter, multiply by 9.524.

<sup>a</sup> Adjusted for randomization, sex, nutritional risk screening score, study center, Barthel scale, main diagnosis, cardiovascular disease, renal disease, and cancer.

$P = .23$ ) for the low and moderate CRP groups, respectively, and an adjusted OR of 1.24 (95% CI, 0.51-3.00;  $P = .64$ ) for the high CRP group.

### Effect of Nutritional Support on Secondary Outcomes According to Inflammation Groups

We also conducted several analyses to investigate the association of nutritional support with different secondary short-term outcomes measured at 30 days and long-term outcomes measured at 180 days (Table 2). For 180-day mortality and major complications, patients with high inflammation on admission tended to benefit less from nutritional support (180-d mortality: adjusted OR, 0.95; 95% CI, 0.58-1.55;  $P = .82$ ; major complications: adjusted OR, 1.19; 95% CI, 0.59-2.38;  $P = .63$ ), but these results were not significant in the interaction analysis. For other secondary end points, results remained robust with no evidence of interaction due to baseline inflammation status.


### Association of Nutritional Support With CRP Kinetics

Finally, we investigated whether nutritional support was associated with CRP kinetics during the first 7 days of inpatient treatment. As shown in **Figure 3**, CRP levels increased from baseline to day 2 and thereafter decreased stepwise with no difference between patients in the intervention group and the control group at any day. The mean (SD) CRP levels for the control and intervention groups on day 1 were 70.93 (2.72) mg/L and 72.61 (2.77) mg/L, respectively. On day 2, these increased to 101.08 (7.72) mg/L and 98.48 (7.80) mg/L, respectively, before decreasing to 45.76 (2.74) mg/L and 50.66 (3.09) mg/L, respectively, on day 7.

## Discussion

The key findings of this secondary analysis investigating the effect of nutritional support among hospitalized patients according to their baseline inflammatory status are 2-fold. First, we found that patients with high baseline inflammation (ie, CRP levels >100 mg/L) were not associated with a benefit from nutritional support with regard to 30-day mortality (ie, the primary end point of this analysis), with a significant result in interaction analysis. Patients with low and moderate inflammation were associated with a significant reduction in 30-day mortality, similar to the overall population. These results remained similar in a subgroup analysis limited to patients with a systemic infection as main admission diagnosis, suggesting that inflammation rather than infection was the main driver of results. Second, we did not find that nutritional support was associated with

**Figure 3. C-Reactive Protein (CRP) Kinetics Within the First 7 Days of Inpatient Treatment According to Randomization Group**



To convert CRP to nanomoles per liter, multiply by 9.524.



inflammation as mirrored by a similar kinetic profile of CRP levels over the first 7 days of inpatient treatment among individuals with and without nutritional support.

Recently, there have been several studies showing that nutritional support has a positive effect on clinical outcomes among patients with malnourishment, particularly among medical patients with multiple illnesses and comorbidities.<sup>4,15,16</sup> Nevertheless, because trials in some populations have reported negative results, it has been hypothesized that not all patients would have the same response to nutrition, emphasizing the concept of personalized nutrition.<sup>17-19</sup> Inflammation could be a key factor, which could explain these differences.<sup>20</sup> In fact, there is a strong biological explanation for why inflammation is associated with the effect of nutritional support on patient outcomes. Previous studies have found that inflammation because of acute or chronic disease causes metabolic changes by influencing different pathways.<sup>21,22</sup> Inflammation has effects on appetite and food intake, gastrointestinal functioning of the stomach and gut, and, on a cellular level, on insulin resistance, among others.<sup>23</sup> Among other mechanisms, these effects are mediated by circulating cytokines released as part of the systemic inflammatory response.<sup>24</sup> Their stress-response release during illness plays an integral role in the systemic inflammatory response, and several studies have found cytokines to be associated with disease-related anorexia, weight loss, decline in cognitive function, frailty, and anemia. For example, interleukin-6 and tumor necrosis factor- $\alpha$  interact with brain circuitries that control food intake, delayed gastric emptying, and muscle catabolism.<sup>25</sup> Interestingly, the cytokine-induced downregulation of food intake during acute illness may also have a beneficial biological role, given that high intake of nutrition during severest illness (ie, overfeeding) has been shown to reduce autophagy, a mechanism important for cell detoxication during illness.<sup>26-28</sup> These observations have also been confirmed in several clinical trials that report no benefit from full-replacement feeding among patients who are critically ill.<sup>29,30</sup> The findings of our study, which looked at a lower-risk patient population in medical wards, are in line with these observations. Overall, they demonstrate that patients do benefit from nutritional support, but those with initially very high levels of CRP and thus marked inflammation may not respond. Of note, our subgroup analysis limited to patients with systemic infection also suggests that it is inflammation and not infection that is driving these results. Individualized nutritional support in these cases even tends to have a harmful effect on 30-day mortality. This finding would also be in line with data observed in patients who are critically ill, who typically have a very strong systemic inflammatory response. Thus, our findings support the concept of individualized nutritional support based on a patient's initial presentation and markers of inflammation, possibly with lower targets for those patients with higher baseline levels of inflammation. However, this hypothesis needs confirmation in prospective trials.

We also investigated whether the association of inflammation and nutrition was bidirectional, ie, whether nutritional support would also be associated with inflammation mirrored by the kinetics of CRP levels over time. However, there was no difference in inflammation during the first 7 days of inpatient treatment for those with and without nutritional support. Thus, there is no evidence from our analysis that the modulation of inflammation through nutritional support in acute situations would be responsible for the positive effects seen on outcomes in previous trials. It is still possible that nutrition has beneficial effects in chronic situations, eg, by modulation of low-grade inflammation. Future trials should look at this particular question to better understand the pathophysiology regarding the effects of nutrition on outcome.

### Strengths and Limitations

To our knowledge, this is the first large-scale analysis to investigate whether inflammation is associated with response to nutritional support based on a secondary analysis of a randomized clinical trial. However, we are aware of several limitations. First, we only measured CRP levels and did not look at other cytokines, which could have delivered more detailed information. Second, the sample size may have been too small to find significant interactions in some of the outcomes investigated. Third, we did not adjust our analysis for all possible confounders; therefore, there could

still be a residual confounding of our analysis. Fourth, because it is a secondary analysis, our results are hypothesis generating rather than definite and require validation in an independent sample.

---

## Conclusions

Based on this secondary analysis of a multicenter randomized clinical trial, patients' inflammatory status at admission was associated with their response to nutritional support. These findings may help to better individualize nutritional support based on patients' initial presentation and markers of inflammation.

---

### ARTICLE INFORMATION

**Accepted for Publication:** January 17, 2020.

**Published:** March 10, 2020. doi:10.1001/jamanetworkopen.2020.0663

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](#). © 2020 Merker M et al. *JAMA Network Open*.

**Corresponding Author:** Philipp Schuetz, MD, MPH, Medical University Department, University of Basel, Kantonsspital Aarau, Tellstrasse 15, Tellstrasse, CH-5001 Aarau, Switzerland ([philipp.schuetz@ksa.ch](mailto:philipp.schuetz@ksa.ch)).

**Author Affiliations:** Medical University Department, University of Basel, Kantonsspital Aarau, Aarau, Switzerland (Merker, Bolliger, Mueller, Schuetz); University of Basel, Basel, Switzerland (Felder, Gueissaz, Schuetz); Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland (Tribolet); Internal Medicine, Kantonsspital Muensterlingen, Muensterlingen, Switzerland (Kägi-Braun, Hoess, Pavlicek); New York Academy of Sciences, New York (Gomes); Internal Medicine and Endocrinology/Diabetes, Kantonsspital St Gallen, St Gallen, Switzerland (Bilz, Sigrist, Brändle); Internal Medicine, Kantonsspital Luzern, Luzern, Switzerland (Henzen); Internal Medicine, Kantonsspital Solothurn, Solothurn, Switzerland (Thomann); Internal Medicine, Kantonsspital Baselland, Baselland, Switzerland (Rutishauser); Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland (Aujesky, Rodondi, Donzé); Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland (Rodondi); Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts (Donzé); Division of Diabetology, Endocrinology, Nutritional Medicine, and Metabolism, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland (Stanga).

**Author Contributions:** Dr Schuetz had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Merker and Mss Felder and Gueissaz are equally contributing co-first authors.

**Concept and design:** Felder, Gueissaz, Kägi-Braun, Hoess, Stanga, Mueller, Schuetz.

**Acquisition, analysis, or interpretation of data:** Merker, Felder, Gueissaz, Bolliger, Tribolet, Gomes, Pavlicek, Bilz, Sigrist, Brändle, Henzen, Thomann, Rutishauser, Aujesky, Rodondi, Donzé, Stanga, Mueller, Schuetz.

**Drafting of the manuscript:** Merker, Felder, Gueissaz, Hoess, Stanga, Schuetz.

**Critical revision of the manuscript for important intellectual content:** Bolliger, Tribolet, Kägi-Braun, Gomes, Pavlicek, Bilz, Sigrist, Brändle, Henzen, Thomann, Rutishauser, Aujesky, Rodondi, Donzé, Stanga, Mueller, Schuetz.

**Statistical analysis:** Merker, Felder, Gueissaz, Schuetz.

**Obtained funding:** Henzen, Stanga, Mueller, Schuetz.

**Administrative, technical, or material support:** Bolliger, Gomes, Hoess, Pavlicek, Henzen, Aujesky, Rodondi, Donzé, Stanga, Mueller, Schuetz.

**Supervision:** Bilz, Brändle, Donzé, Stanga, Mueller, Schuetz.

**Conflict of Interest Disclosures:** Dr Stanga reported receiving grants from Nestlé Health Science, Fresenius Kabi, Abbott Nutrition, and Baxter outside the submitted work. Dr Schuetz reported receiving funding support from Nestlé, Abbott Nutrition, Thermofisher, Roche Diagnostics, and BioMerieux outside the submitted work. No other disclosures were reported.

**Funding/Support:** The trial was funded by grant PPOOP3\_150531 from the Swiss National Science Foundation and grants 1410.000.058 and 1410.000.044 from the Research Council of the Kantonsspital Aarau.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement:** See Supplement 3.

**Additional Contributions:** We thank all the contributing authors from the Effect of Early Nutritional Support on Frailty, Functional Outcomes, and Recovery of Malnourished Medical Inpatients Trial (EFFORT), namely Rebecca Fehr, RN (University Hospital Zurich), Valerie Baechli, RN (Kantonsspital Aarau), Martina Geiser, RN (Kantonsspital Aarau), Manuela Deiss, RN (Kantonsspital Aarau), Alexander Kutz, MD (Kantonsspital Aarau), Sarah Schmid, RN (Kantonsspital St Gallen), Carmen Benz, RN (Kantonsspital St Gallen), Silvia Mattmann, RN (Kantonsspital Luzern), and Claudia Brand, RN (Solothurner Kantonsspital), for their support.

## REFERENCES

1. Norman K, Pichard C, Lochs H, Pirlich M. Prognostic impact of disease-related malnutrition. *Clin Nutr*. 2008;27(1):5-15. doi:10.1016/j.clnu.2007.10.007
2. Felder S, Lechtenboehmer C, Bally M, et al. Association of nutritional risk and adverse medical outcomes across different medical inpatient populations. *Nutrition*. 2015;31(11-12):1385-1393. doi:10.1016/j.nut.2015.06.007
3. Reber E, Gomes F, Vasiloglou MF, Schuetz P, Stanga Z. Nutritional risk screening and assessment. *J Clin Med*. 2019;8(7):E1065. doi:10.3390/jcm8071065
4. Schuetz P, Fehr R, Baechli V, et al. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. *Lancet*. 2019;393(10188):2312-2321. doi:10.1016/S0140-6736(18)32776-4
5. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. *Am J Clin Nutr*. 2006;83(4):735-743. doi:10.1093/ajcn/83.4.735
6. Braun N, Hoess C, Kutz A, et al. Obesity paradox in patients with community-acquired pneumonia: is inflammation the missing link? *Nutrition*. 2017;33:304-310. doi:10.1016/j.nut.2016.07.016
7. Lim SL, Ong KC, Chan YH, Loke WC, Ferguson M, Daniels L. Malnutrition and its impact on cost of hospitalization, length of stay, readmission and 3-year mortality. *Clin Nutr*. 2012;31(3):345-350. doi:10.1016/j.clnu.2011.11.001
8. Sorensen J, Kondrup J, Prokopowicz J, et al; EuroOOPS study group. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. *Clin Nutr*. 2008;27(3):340-349. doi:10.1016/j.clnu.2008.03.012
9. Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. *Clin Nutr*. 2017;36(1):49-64. doi:10.1016/j.clnu.2016.09.004
10. Soeters P, Bozzetti F, Cynober L, Elia M, Shenkin A, Sobotka L. Meta-analysis is not enough: the critical role of pathophysiology in determining optimal care in clinical nutrition. *Clin Nutr*. 2016;35(3):748-757. doi:10.1016/j.clnu.2015.08.008
11. Ross SD. The CONSORT statement. *JAMA*. 1996;276(23):1877. doi:10.1001/jama.1996.03540230027024
12. Schuetz P, Fehr R, Baechli V, et al. Design and rationale of the Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Malnourished Medical Inpatients Trial (EFFORT): a pragmatic, multicenter, randomized-controlled trial. *Int J Clin Trials*. 2018;5(3):77. doi:10.18203/2349-3259.ijct20182085
13. Hersberger L, Bargetzi L, Bargetzi A, et al. Nutritional risk screening (NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial. *Clin Nutr*. 2019;S0261-5614(19)33171-1. doi:10.1016/j.clnu.2019.11.041
14. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. *Ann N Y Acad Sci*. 1982;389:406-418. doi:10.1111/j.1749-6632.1982.tb22153.x
15. Gomes F, Baumgartner A, Bounoure L, et al. Association of nutritional support with clinical outcomes among medical inpatients who are malnourished or at nutritional risk: an updated systematic review and meta-analysis. *JAMA Netw Open*. 2019;2(11):e1915138. doi:10.1001/jamanetworkopen.2019.15138
16. Deutz NE, Matheson EM, Matarese LE, et al; NOURISH Study Group. Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: a randomized clinical trial. *Clin Nutr*. 2016;35(1):18-26. doi:10.1016/j.clnu.2015.12.010
17. Marik PE. Nutritional support among medical inpatients—feed the cold (and malnourished) and starve the febrile. *JAMA Netw Open*. 2019;2(11):e1915707. doi:10.1001/jamanetworkopen.2019.15707
18. Marik PE. Feeding critically ill patients the right 'whey': thinking outside of the box: a personal view. *Ann Intensive Care*. 2015;5(1):51. doi:10.1186/s13613-015-0051-2

19. Hooper MH, Marik PE. Controversies and misconceptions in intensive care unit nutrition. *Clin Chest Med*. 2015;36(3):409-418. doi:10.1016/j.ccm.2015.05.013
20. Merker M, Gomes F, Stanga Z, Schuetz P. Evidence-based nutrition for the malnourished, hospitalised patient: one bite at a time. *Swiss Med Wkly*. 2019;149:w20112. doi:10.4414/smw.2019.20112
21. Schuetz P. Food for thought: why does the medical community struggle with research about nutritional therapy in the acute care setting? *BMC Med*. 2017;15(1):38. doi:10.1186/s12916-017-0812-x
22. Schuetz P. "Eat your lunch!"—controversies in the nutrition of the acutely, non-critically ill medical inpatient. *Swiss Med Wkly*. 2015;145:w14132. doi:10.4414/smw.2015.14132
23. Felder S, Braun N, Stanga Z, et al. Unraveling the link between malnutrition and adverse clinical outcomes: association of acute and chronic malnutrition measures with blood biomarkers from different pathophysiological states. *Ann Nutr Metab*. 2016;68(3):164-172. doi:10.1159/000444096
24. Schütz P, Bally M, Stanga Z, Keller U. Loss of appetite in acutely ill medical inpatients: physiological response or therapeutic target? *Swiss Med Wkly*. 2014;144:w13957. doi:10.4414/smw.2014.13957
25. Kuhlmann MK, Levin NW. Potential interplay between nutrition and inflammation in dialysis patients. *Contrib Nephrol*. 2008;161:76-82. doi:10.1159/000129759
26. Casaer MP, Van den Berghe G. Nutrition in the acute phase of critical illness. *N Engl J Med*. 2014;370(13):1227-1236. doi:10.1056/NEJMra1304623
27. Gunst J, Derese I, Aertgeerts A, et al. Insufficient autophagy contributes to mitochondrial dysfunction, organ failure, and adverse outcome in an animal model of critical illness. *Crit Care Med*. 2013;41(1):182-194. doi:10.1097/CCM.0b013e3182676657
28. Vanhorebeek I, Gunst J, Derde S, et al. Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. *J Clin Endocrinol Metab*. 2011;96(4):E633-E645. doi:10.1210/jc.2010-2563
29. Vanderheyden S, Casaer MP, Kesteloot K, et al. Early versus late parenteral nutrition in ICU patients: cost analysis of the EPaNIC trial. *Crit Care*. 2012;16(3):R96. doi:10.1186/cc11361
30. Rice TW, Wheeler AP, Thompson BT, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. *JAMA*. 2012;307(8):795-803. doi:10.1001/jama.2012.137

#### SUPPLEMENT 1.

##### Trial Protocol

#### SUPPLEMENT 2.

eTable. Baseline Characteristics According to Randomization Arm Overall and Stratified by CRP Status

#### SUPPLEMENT 3.

##### Data Sharing Statement